When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

The startup, which has already raised more than half a billion dollars, released Phase 2 results that could position its drug ...

Eli Lilly and Company will attend the 43rd Annual J.P. Morgan Healthcare Conference, Jan. 13-16, 2025. David A. Ricks, Lilly chair and CEO, will participate in a fireside chat on Tuesday, Jan. 14 at 5 ...

In a report released today, Terence Flynn from Morgan Stanley reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report), with a ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 492.13% and ...

The activation marked the latest phase of the ongoing It Takes 2 campaign from Boehringer Ingelheim and Eli Lilly.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Product approvals in regenerative medicine and rare diseases are among the highlights in our recap of recent FDA regulatory decisions.

Eli Lilly is seeking to end a lawsuit filed by a pharmacy trade group against the Food and Drug Administration (FDA) by ...

Eli Lilly has asked to join in opposing a lawsuit brought by compounding pharmacies against the U.S. Food and Drug ...

Zepbound (tirzepatide) is reshaping the competitive landscape in obesity treatment, challenging Novo Nordisk A/S' (NYSE:NVO) ...

By itself, it’s not enough, but body mass index has years of evidence behind it and still has a place in clinical assessments ...